Left ventricular chamber dilatation and systolic dysfunction developed in 14% of hypertrophic cardiomyopathy patients over 10.3 years and was associated with significantly worse event-free survival (P<0.05).
Cohort (n=139)
What is the incidence and prognosis of left ventricular chamber dilatation in patients with hypertrophic cardiomyopathy?
In patients with hypertrophic cardiomyopathy, left ventricular chamber dilatation occurs in about 1.5% of patients per year and is associated with worse event-free survival and quality of life.
Absolute Event Rate: 14% vs 86%
BACKGROUND: To determine the incidence and prognosis of left ventricular dilatation and systolic dysfunction in 139 patients with hypertrophic cardiomyopathy during long term follow up. METHODS: Left ventricular chamber dilatation and systolic dysfunction (both together referred to as left ventricular chamber dilatation) were determined echocardiographically. Chamber dilatation was defined as an increase in the left ventricular end diastolic diameter of > 2% per year combined with a decrease in midventricular systolic fractional shortening of > 2% per year of follow up 10.3 (SD 6) years. The predictive value for left ventricular chamber dilatation of clinical, invasive, and echocardiographic variables and its prognosis were assessed. RESULTS: In 119 of 139 individuals (86%), left ventricular chamber size and systolic function remained stable (group 1), and in 20/139 patients (14%) left ventricular chamber dilatation occurred during follow up (group 2). At baseline examination, symptoms such as dyspnoea and syncope occurred less often in group 1 than in group 2; New York Heart Association classification was lower in group 1 than in group 2 (P = 0.001). Left ventricular mass index relative to sex specific normal values was increased by 18% in group 1 and by 41% in group 2 (P = 0.04). Cumulative survival rates were slightly although not significantly higher in group 1 than in group 2. Event-free survival was significantly higher in group 1 than in group 2 (P < 0.05). CONCLUSIONS: (1) The development of left ventricular chamber dilatation and systolic dysfunction in hypertrophic cardiomyopathy occurs in approximately 1.5% of the patients per year. (2) Factors associated with left ventricular dilatation are dyspnoea, syncope, a higher functional classification, and a higher degree of left ventricular hypertrophy. (3) Patients with chamber dilatation have a worse prognosis than those without, particularly regarding quality of life.
Seiler et al. (Wed,) conducted a cohort in Hypertrophic cardiomyopathy (n=139). Left ventricular chamber dilatation and systolic dysfunction vs. Stable left ventricular chamber size and systolic function was evaluated on Incidence of left ventricular chamber dilatation and systolic dysfunction. Left ventricular chamber dilatation and systolic dysfunction developed in 14% of hypertrophic cardiomyopathy patients over 10.3 years and was associated with significantly worse event-free survival (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: